RBC Capital Upgrades BioCryst Pharma (BCRX) to Outperform, 'Doc Survey Suggesting Good Orladeyo Metrics'

September 18, 2023 5:06 AM EDT Send to a Friend
(Updated - September 18, 2023 6:18 AM EDT)

RBC Capital analyst Brian Abraham upgraded BioCryst Pharma (NASDAQ: BCRX) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login